Dewi G.
- Country
- France
- Department
- #3008: Rhumatologie
Research Overview
- Efficacy of Baricitinib in Relapsing or Naïve Dermatomyositis: A Randomized, Placebo-Controlled Trial
- Efficacy and Safety of Subcutaneous Anifrolumab Versus Placebo in Adult Idiopathic Inflammatory Myopathies: A Phase III, Double-Blind, Multicenter Study
- Evaluation of Rapcabtagene Autoleucel Versus Standard Treatment in Severe Refractory Idiopathic Inflammatory Myopathies: A Phase 2 Randomized Controlled Trial
Data & Insights
Has run more than one trial at 19 of 110 partner sites.
Specializations
Inflammatory Myopathies
This investigator specializes in treating severe refractory idiopathic inflammatory myopathies (IIM), with particular expertise in developing innovative therapeutic approaches for difficult-to-treat cases.
- Advanced Cell Therapy Applications
- Inflammatory Myopathy Management
- Immunological Response Assessment
The research focuses on evaluating novel therapeutic options for patients with treatment-resistant conditions.
Dermatomyositis Research
Expertise extends to the treatment of dermatomyositis, exploring targeted therapeutic approaches using JAK1/2 inhibition for both relapsing and treatment-naïve patients.
- Novel Treatment Protocols
- Steroid-Sparing Strategies
- Disease Activity Monitoring
The investigator's work involves evaluating treatments that could reduce dependence on traditional corticosteroid therapy.
Autoimmune Disorders
Specializes in treating polymyositis and dermatomyositis according to current international classification criteria, with focus on subcutaneous therapeutic interventions.
- Disease Activity Assessment
- Long-term Treatment Outcomes
- Standard of Care Enhancement
The research encompasses evaluation of novel biological therapies in combination with standard treatment approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.